Rosen Comments on Prospects for COVID-19 Vaccine This Year
July 30, 2020
Memphis Business Journal
Partner David Rosen was quoted in a Memphis Business Journal article, “A COVID-19 vaccine this year? It’s a long shot, but it’s possible,” about drug companies considering the use of a little-known regulatory tool to push their COVID-19 vaccines into Americans’ hands before the end of the year.
Rosen, who chairs the firm’s FDA regulatory practice, said the government’s decision to enact the Public Readiness and Emergency Preparedness (PREP) Act in response to the COVID-19 outbreak limits the legal repercussions that drugmakers could face if their COVID-19 products cause physical injury, death and other ill effects to users.
(Subscription required.)
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."